Evidence map›Paper›PMID 38976323›Full record

ArticleCancer communications (London, England)2024

Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy.

Michael Schnekenburger, Anne Lorant, Sruthi Reddy Gajulapalli, Ridhika Rajora, Jin-Young Lee, Aloran Mazumder, Haeun Yang, Christo Christov, Hyoung Jin Kang, Bernard Pirotte and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michael SchnekenburgerLaboratoire de Biologie Moléculaire et Cellulaire du Cancer, Luxembourg, Luxembourg.
Anne LorantLaboratoire de Biologie Moléculaire et Cellulaire du Cancer, Luxembourg, Luxembourg.
Sruthi Reddy GajulapalliResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Ridhika RajoraResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Jin-Young LeeResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Aloran MazumderResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Haeun YangResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Christo ChristovFaculté de Médecine, Université de Lorraine, Vandœuvre-lès-Nancy, France.
Hyoung Jin KangDepartment of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, Republic of Korea.
Bernard PirotteLaboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.
Marc DiederichResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.ORCID 0000-0003-0115-4725

Funding

MEST of Korea for Tumor Microenvironment Global Core Research Center 2011-0030001National Research Foundation of Korea 2011-0030001National Research Foundation of Korea 370C-20220063National Research Foundation of Korea Brain Korea (BK21) PLUS programSeoul National University 370C-20160062
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveSirtuin 1Sirtuin 2AnimalsAntineoplastic AgentsEnergy MetabolismHumansMiceAntineoplastic AgentsSIRT1 protein, humanSirtuin 1Sirtuin 2

Identifiers

PMID38976323
PMCPMC11337917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.